Last reviewed · How we verify
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to \< 4 years.
Details
| Lead sponsor | Aimmune Therapeutics, Inc. |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 146 |
| Start date | Thu Dec 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Peanut Allergy
Interventions
- AR101 powder provided in capsules & sachets
- Placebo powder provided in capsules & sachets
Countries
France, United Kingdom, United States, Germany